"Differential Knockout Of A Heterozygous Allele Of Lrrk2" in Patent Application Approval Process (USPTO 20240000970).
In: Pain & Central Nervous System Week, 2024-01-26, S. 1827-1827
serialPeriodical
Zugriff:
EmendoBio Inc. has filed a patent application outlining a method for modifying a mutant allele of the LRRK2 gene, which is associated with monogenic Parkinson's disease. The method involves using CRISPR technology to introduce a composition containing a CRISPR nuclease and an RNA molecule into the cell, resulting in a double-strand break in the mutant allele. The RNA molecule specifically targets the mutation associated with Parkinson's disease. This research has potential implications for the treatment and prevention of monogenic Parkinson's disease. For more detailed information, please refer to the full patent application. [Extracted from the article]
Copyright of Pain & Central Nervous System Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Differential Knockout Of A Heterozygous Allele Of Lrrk2" in Patent Application Approval Process (USPTO 20240000970).
|
---|---|
Zeitschrift: | Pain & Central Nervous System Week, 2024-01-26, S. 1827-1827 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6394 (print) |
Schlagwort: |
|
Sonstiges: |
|